AbangeLabsUnder-5 utility evidence is no longer a side quest—if infant/toddler HRQoL is weak, the cost-effectiveness model is fragile from day one. https://www.mattheneus.com/editorial/infant-toddler-utility-measurement-cost-effectiveness-governance-playbook-2026-04-02 #HTA #HealthEconomics #Pharma
Infant and toddler utility measurement is becoming a first-order cost-effectiveness design problem
On 1 April 2026, Quality of Life Research published a recommendations paper on measuring health-related quality of life in infants and toddlers and a companion empirical study using the EuroQol toddler and infant populations instrument in young children. Together they sharpen a familiar but under-managed market-access risk: if utility evidence for children under 5 is weak, proxy-reported, or mapped late, the cost-effectiveness model becomes fragile.